Valaciclovir



Indications and Reactions:

Role Indications Reactions
Primary
Product Used For Unknown Indication 31.9%
Herpes Zoster 27.5%
Stem Cell Transplant 7.7%
Chronic Lymphocytic Leukaemia 3.3%
Herpes Virus Infection 3.3%
Bronchopulmonary Aspergillosis 2.2%
Encephalitis Herpes 2.2%
Herpes Simplex 2.2%
Hypertension 2.2%
Immunosuppressant Drug Therapy 2.2%
Infection 2.2%
Overdose 2.2%
Prophylaxis 2.2%
Stomatitis 2.2%
Contraception 1.1%
Cytomegalovirus Gastroenteritis 1.1%
Epilepsy 1.1%
Genital Herpes 1.1%
Glioblastoma 1.1%
Herpes Zoster Ophthalmic 1.1%
Drug Ineffective 8.6%
Stevens-johnson Syndrome 8.6%
Toxic Epidermal Necrolysis 8.6%
Depressed Level Of Consciousness 5.7%
Herpes Zoster 5.7%
Incorrect Dose Administered 5.7%
Myelitis Transverse 5.7%
Neurotoxicity 5.7%
Overdose 5.7%
Product Substitution Issue 5.7%
Pyrexia 5.7%
Toxicity To Various Agents 5.7%
Abdominal Distension 2.9%
Acute Graft Versus Host Disease In Skin 2.9%
Agranulocytosis 2.9%
Alopecia Areata 2.9%
Altered State Of Consciousness 2.9%
Biliary Cirrhosis Primary 2.9%
Blood Creatinine Increased 2.9%
Confusional State 2.9%
Secondary
Product Used For Unknown Indication 53.6%
Prophylaxis 5.6%
Cardiac Failure 4.7%
Lung Disorder 4.7%
Herpes Zoster 4.3%
Hiv Infection 3.3%
Chronic Lymphocytic Leukaemia 3.1%
Febrile Bone Marrow Aplasia 2.9%
Acute Myeloid Leukaemia 2.3%
Haematological Malignancy 2.3%
Stem Cell Transplant 1.7%
Graft Versus Host Disease 1.6%
Drug Use For Unknown Indication 1.4%
Hodgkin's Disease 1.4%
Stomatitis 1.4%
Antiviral Prophylaxis 1.2%
Diffuse Large B-cell Lymphoma 1.2%
Herpes Virus Infection 1.2%
Hodgkin's Disease Stage Iv 1.2%
Myelodysplastic Syndrome 1.2%
Eosinophilia 7.5%
Hypertriglyceridaemia 7.5%
Renal Failure 7.5%
Agranulocytosis 5.7%
Cataract 5.7%
Completed Suicide 5.7%
Gastrointestinal Haemorrhage 5.7%
Hepatitis Cholestatic 5.7%
Pyrexia 5.7%
Rectal Haemorrhage 5.7%
Renal Failure Acute 5.7%
Generalised Erythema 3.8%
Hallucination, Visual 3.8%
Mixed Liver Injury 3.8%
Pleural Effusion 3.8%
Renal Impairment 3.8%
Toxicity To Various Agents 3.8%
Vomiting 3.8%
Weight Increased 3.8%
Abdominal Pain 1.9%
Concomitant
Product Used For Unknown Indication 33.7%
Prophylaxis 13.7%
Diffuse Large B-cell Lymphoma 12.2%
Multiple Myeloma 3.8%
T-cell Lymphoma 3.5%
Chronic Lymphocytic Leukaemia 3.3%
Infection Prophylaxis 2.9%
Acute Myeloid Leukaemia 2.8%
Plasma Cell Myeloma 2.6%
Pain 2.4%
Hypertension 2.3%
Drug Use For Unknown Indication 2.2%
Hiv Infection 2.2%
Antiviral Prophylaxis 2.1%
Mantle Cell Lymphoma 2.0%
Premedication 1.9%
B-cell Lymphoma 1.8%
Antifungal Prophylaxis 1.7%
Constipation 1.5%
Acute Lymphocytic Leukaemia 1.4%
Sepsis 11.6%
Pulmonary Embolism 8.7%
Pyrexia 7.2%
Renal Failure Acute 6.9%
Febrile Neutropenia 6.5%
Pneumonia 6.5%
Constipation 5.8%
Septic Shock 5.1%
Renal Failure 4.3%
Cardiomyopathy 4.0%
Vertigo 4.0%
Death 3.6%
Infection 3.6%
Nausea 3.6%
Thrombocytopenia 3.6%
Cytomegalovirus Infection 3.2%
Deep Vein Thrombosis 3.2%
Cytolytic Hepatitis 2.9%
Malaise 2.9%
Pancytopenia 2.9%
Interacting
Hiv Infection 41.7%
Blood Cholesterol Increased 16.7%
Erysipelas 16.7%
Herpes Simplex 8.3%
Herpes Zoster 8.3%
Hyperpyrexia 8.3%
Rash Papular 50.0%
Red Blood Cell Count Abnormal 50.0%